TEST:

HER2DX

In Annals of Oncology, @G_Villacampa and coll. report on the association of HER2DX scores with pCR including according to treatment regimens, and on survival outcome according to pCR status 👇 https://t.co/4CDxUZswgA @stolaney1 @prat_aleix #bcsm (@Annals_Oncology)

New 📰published in @Annals_Oncology on the association of #HER2DX with pathological complete response and survival outcomes in #HER2-positive #BreastCancer. @G_Villacampa @stolaney1 @EMittendorfMD @prat_aleix @adawaksmd @vitti10 @awolff @patri0608 @sltc21 https://t.co/6RBjvvkGmI (@DFCI_BreastOnc)

REVEAL GENOMICS® ANNOUNCES POSITIVE TOP-LINE RESULTS FOR HER2DX® IN MEDSIR'S PHERGAIN TRIAL #her2 #breastcancer #bcsm ⁦@prat_aleix⁩ ⁦@JavierCortesMD⁩ 👏🏻👏🏻👏🏻 https://t.co/cmbnyFli2U (@FernandoOnco)

Dear Colleagues, A New @OncoAlert 🚨Newsletter comes out Tomorrow Thursday June 15, 2023 To Register go to https://t.co/yzt83gqQkF Covering: ✅HER2DX in #BreastCancer by @stolaney1 & @prat_aleix ✅ ⬇️carb diets & Breast Cancer Survival ✅OncoAlert ☢️Consensus on PROSPECT⚒️ ✅… https://t.co/efD8tgxBkL (@OncoAlert)

Join our Co-founder and CSO, Dr. Aleix Prat @prat_aleix, in this Workshop with new data about #HER2DX presented at #ESMOBreast23 Next Thursday, May 25th at 5 pm (CEST) Register here: https://t.co/po1FKv4l8V #breastcancer #precisiononcology (@RevealGenomics)

Can we predict HER2-low status using #HER2DX ERBB2 mRNA within HER2-negative breast cancer? Yes!! # ESMOBreast2023 ⁦@myESMO⁩ Next step is to test its value following T-DXd…working on it with ⁦@ScaltritiLab⁩ ⁦@esther_sanfeliu⁩ ⁦@fara_bm⁩ (@prat_aleix)

Last day of #ESMOBreast23 and #HER2DX is still hot topic!!! ⭐️@ChristineDesme2 on Key Takeaways #HERDX scores and validations #breastcancer #precisiononcology (@RevealGenomics)

Dr. Giuseppe Curigliano @curijoey on #HER2DX “It is a tool that can impact early stages in HER2+ #breastcancer. We could identify those low-risk patients who do not even need therapy” #precisiononcology #ESMOBreast23 (@RevealGenomics)

Validation of #HER2DX in ⁦@idibell_cat⁩ ⁦@ICO_oncologia⁩ BiOnHER clinical neoadj trial of THP in HER2+ breast cancer led by ⁦@SoniaPernas⁩ #COI (@prat_aleix)

7P The standardized #HER2DX ERBB2 mRNA score predicts the clinical status of HER2 (positive, low and zero) in #breastcancer #precisiononcology #ESMOBreast23 (@RevealGenomics)

13P. Analytical validation has proved #HER2DX to be reproducible and robust between laboratories. #breastcancer #precisiononcology #ESMOBreast23 (@RevealGenomics)

6P The #HER2DX score is associated with risk of recurrence among patients with small, node negative HER2+ breast tumors, and, if validated, may help in tailoring treatments for this disease. @PTarantinoMD #breastcancer #precisiononcology #ESMOBreast23 (@RevealGenomics)

#ESMOBreast23 HER2DX and pathological complete response in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies 💥HER2DX may assist in the selection of neoadjuvant therapy in HER2-positive BC. Presented by Dr. Adrienne Waks @OncoAlert @myESMO (@dr_yakupergun)

Don’t miss our poster presentation on the combined #HER2DX analysis of APT & ATEMPT. Can a comprehensive clinical/biologic characterization of small, node-negative HER2+ breast tumors improve prognostication? @stolaney1 @prat_aleix @G_Villacampa (@PTarantinoMD)

📯New Clinical Case: female 49 yo cT2 cN0 HER2+ (ER 80%, PR 25%, ki67: 50%, HER2 2+ (FISH+), TILs 90%). Based on her #HER2DX test, which treatment would you select? #breastcancer #biomarker #precisionMedicine (@CejalvoM)

In march 2023, we published in @JNCI_Now a study evaluating HER2DX ERBB2 mRNA as a predictor of T-DM1 response in HER2+ MBC Prof. Bertucci and colleagues wrote a letter to the editor, providing more evidence of the value of ERBB2 mRNA as a predictor of T-DM1, looking at I-ISPY2… https://t.co/Y5WPzpqTv5 (@prat_aleix)

“Predictors of #pCR are not the same than those predictors of prognosis as shown here and confirmed by #HER2DX ”, our co-founder and CSO, @prat_aleix at @SG_BCC #breastcancer #precisiononcology ()

“Single #biomarker does not capture the underlying biology of #HER2+ tumors; we need multifeatured #biomarkers”, our Co-founder and CSO, @prat_aleix talking about #HER2DX at @SG_BCC right now #breastcancer #precisiononcology ()

HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 https://t.co/l6QlCVpqVN Is there hope for treatment tailoring in HER2 positive metastatic breast cancer? Congrats! Intriguing findings ()

Adjuvant Paclitaxel and Trastuzumab in Node-Negative, HER2-Positive Breast Cancer Long-Term Follow-up - The ASCO Post ⁦@stolaney1⁩ ⁦@PTarantinoMD⁩ #HER2DX #COI ⁦@RevealGenomics⁩ https://t.co/VBGdWfAe7m ()

Out in @TheLancetOncol new results from APT trial. Pacli + trastu confirmed an optimal de-escalation approach in patients with small, node-negative HER2+ #breastcancer. #HER2DX discriminates btw those with excellent (iDFS 94%) an poor prognosis (iDFS 78%). @OncoAlert https://t.co/9zY8F3LnsS ()

Could @HER2DX help you (patient and physician) make the decision to use adjuvant paclitaxel + trastuzumab instead of multi-agent chemo + trastuzumab in pT1cN0/pT2N0 HER2+ breast cancer? #COI ()

Our new article @TheLancetOncol is out! Led by @stolaney1 + colleagues Paclitaxel and trastuzumab is a reasonable treatment standard for patients with small, node- HER2+ breast cancer #HER2DX refines the prognosis for this population https://t.co/vGeDTf0ovK #COI @OncoAlert ()

Num6 HER2DX and pathological complete response in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies @G_Villacampa ()